Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retropective study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1479-5876
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retropective study ; volume:11 ; number:1 ; day:2 ; month:7 ; year:2013 ; pages:1-7 ; date:12.2013
Journal of translational medicine ; 11, Heft 1 (2.7.2013), 1-7, 12.2013
- Urheber
-
Di Lorenzo, Giuseppe
- Beteiligte Personen und Organisationen
-
Perdonà, Sisto
Buonerba, Carlo
Sonpavde, Guru
Gigantino, Vincenzo
Pannone, Giuseppe
Quarto, Giuseppe
Ferro, Matteo
Gaudioso, Gabriella
Terracciano, Daniela
Di Trolio, Rossella
Rescigno, Pasquale
Botti, Gerardo
De Placido, Sabino
Facchini, Gaetano
Ascierto, Paolo A.
Franco, Renato
SpringerLink (Online service)
- DOI
-
10.1186/1479-5876-11-161
- URN
-
urn:nbn:de:1111-2016041443995
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:45 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Di Lorenzo, Giuseppe
- Perdonà, Sisto
- Buonerba, Carlo
- Sonpavde, Guru
- Gigantino, Vincenzo
- Pannone, Giuseppe
- Quarto, Giuseppe
- Ferro, Matteo
- Gaudioso, Gabriella
- Terracciano, Daniela
- Di Trolio, Rossella
- Rescigno, Pasquale
- Botti, Gerardo
- De Placido, Sabino
- Facchini, Gaetano
- Ascierto, Paolo A.
- Franco, Renato
- SpringerLink (Online service)
Ähnliche Objekte (12)
Melanoma: the role of surgery in the era of new therapies
Adjuvant therapy of melanoma with interferon: lessons of the past decade
What have we learned from cancer immunotherapy in the last 3 years?
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
Combination therapy: the next opportunity and challenge of medicine
Melanoma: A model for testing new agents in combination therapies
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Highlights and summary of the 28th annual meeting of the Society for Immunotherapy of Cancer
Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma
Lean oncology: a new model for oncologists
The influence of diet on anti-cancer immune responsiveness
Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials
Melanoma: the role of surgery in the era of new therapies
Adjuvant therapy of melanoma with interferon: lessons of the past decade
What have we learned from cancer immunotherapy in the last 3 years?
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
Combination therapy: the next opportunity and challenge of medicine
Melanoma: A model for testing new agents in combination therapies
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Highlights and summary of the 28th annual meeting of the Society for Immunotherapy of Cancer
Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma
Lean oncology: a new model for oncologists
The influence of diet on anti-cancer immune responsiveness
Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials
Melanoma: the role of surgery in the era of new therapies
Adjuvant therapy of melanoma with interferon: lessons of the past decade
What have we learned from cancer immunotherapy in the last 3 years?
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
Combination therapy: the next opportunity and challenge of medicine
Melanoma: A model for testing new agents in combination therapies
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Highlights and summary of the 28th annual meeting of the Society for Immunotherapy of Cancer
Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma
Lean oncology: a new model for oncologists
The influence of diet on anti-cancer immune responsiveness